← board
BON
distress 2/10 · well-funded / low risk$1.14-5%today-50% from 52w high
Revenue
$19M
Liquidity
$6M
Runway
—
Shares 1y
-52%
Price & events
-32.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-5.0%
1D
-3.1%
1W
-5.8%
1M
-10.9%
3M
-32.9%
6M
-21.9%
1Y
-97.9%
2Y
-100.0%
5Y
-99.9%
All
Overview
- Market Cap
- $4.53M
- Enterprise Value
- $-896.73K
- Volume
- 4.46K
- 52 Week Range
- $1.13 – $2.28
- Total Shares
- 3.97M
- Float Shares
- 5.99M
- Short %
- 0.11%
- % Held by Insiders
- 0.01%
- % Held by Institutions
- 0.26%
- RVOL
- 0.30x
- Beta
- -0.17
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.